Abstract

Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) represent two ends of a disease spectrum with shared clinical, genetic and pathological features. These include near ubiquitous pathological inclusions of the RNA binding protein (RBP) TDP-43, and often the presence of a GGGGCC expansion in the C9ORF72 (C9) gene. Previously we reported that the sequestration of hnRNP H altered the splicing of target transcripts in C9ALS patients (Conlon et al. 2016). Here we show that this signature also occurs in half of 50 post-mortem sporadic, non-C9 ALS/FTD brains. Furthermore, and equally surprisingly, these 'like-C9' brains also contained correspondingly high amounts of insoluble TDP-43, as well as several other disease-related RBPs, and this correlates with widespread global splicing defects. Finally, we show that the like-C9 sporadic patients, like actual C9ALS patients, were much more likely to have developed FTD. We propose that these unexpected links between C9 and sporadic ALS/FTD define a common mechanism in this disease spectrum.

Data availability

All raw RNASeq data from Target ALS samples is immediately made publicly available. Access to the data can be requested by emailing ALSData@nygenome.org.All RNASeq data from the ALS Consortium is made immediately available to all members of the Consortium and with other Consortia with whom we have a reciprocal sharing arrangement. Data have been deposited in the National Center for Biotechnology Information Gene Expression Omnibus (GEO) (accession no. GSE116622). Data will be released upon acceptance.

The following data sets were generated

Article and author information

Author details

  1. Erin G Conlon

    Department of Biological Sciences, Columbia University, New York, United States
    Competing interests
    No competing interests declared.
  2. Delphine Fagegaltier

    Center for Genomics of Neurodegenerative disease, New York Genome Center, New York, United States
    Competing interests
    No competing interests declared.
  3. Phaedra Agius

    Center for Genomics of Neurodegenerative disease, New York Genome Center, New York, United States
    Competing interests
    No competing interests declared.
  4. Julia Davis-Porada

    Department of Biological Sciences, Columbia University, New York, United States
    Competing interests
    No competing interests declared.
  5. James Gregory

    Center for Genomics of Neurodegenerative disease, New York Genome Center, New York, United States
    Competing interests
    No competing interests declared.
  6. Isabel Hubbard

    Center for Genomics of Neurodegenerative disease, New York Genome Center, New York, United States
    Competing interests
    No competing interests declared.
  7. Kristy Kang

    Center for Genomics of Neurodegenerative disease, New York Genome Center, New York, United States
    Competing interests
    No competing interests declared.
  8. Duyang Kim

    Center for Genomics of Neurodegenerative disease, New York Genome Center, New York, United States
    Competing interests
    No competing interests declared.
  9. The New York Genome Center ALS Consortium

  10. Hemali Phatnani

    Center for Genomics of Neurodegenerative Disease, New York Genome Center, New York, United States
    Competing interests
    No competing interests declared.
  11. Neil A Shneider

    Department of Neurology, Columbia University, New York, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3223-7366
  12. James L Manley

    Department of Biological Sciences, Columbia University, New York, United States
    For correspondence
    jlm2@columbia.edu
    Competing interests
    James L Manley, Senior editor, eLife.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8341-1459

Funding

NIH Office of the Director (R35 GM 118136)

  • James L Manley

NIH Office of the Director (5T32GM008798)

  • Erin G Conlon

ALS Association (15-LGCA-234)

  • Hemali Phatnani

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Douglas L Black, University of California, Los Angeles, United States

Ethics

Human subjects: Human post-mortem brain samples were donated for research purposes by next of kin.

Version history

  1. Received: April 23, 2018
  2. Accepted: July 9, 2018
  3. Accepted Manuscript published: July 13, 2018 (version 1)
  4. Version of Record published: August 21, 2018 (version 2)

Copyright

© 2018, Conlon et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 8,426
    views
  • 1,181
    downloads
  • 46
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Erin G Conlon
  2. Delphine Fagegaltier
  3. Phaedra Agius
  4. Julia Davis-Porada
  5. James Gregory
  6. Isabel Hubbard
  7. Kristy Kang
  8. Duyang Kim
  9. The New York Genome Center ALS Consortium
  10. Hemali Phatnani
  11. Neil A Shneider
  12. James L Manley
(2018)
Unexpected similarities between C9ORF72 and sporadic forms of ALS/FTD suggest a common disease mechanism
eLife 7:e37754.
https://doi.org/10.7554/eLife.37754

Share this article

https://doi.org/10.7554/eLife.37754

Further reading

    1. Biochemistry and Chemical Biology
    Aaron D Gitler, John D Fryer
    Insight

    New analyses shift the view that some forms of amyotrophic lateral sclerosis and frontotemporal dementia are due to defects in a single RNA-binding protein.

    1. Biochemistry and Chemical Biology
    2. Plant Biology
    Dietmar Funck, Malte Sinn ... Jörg S Hartig
    Research Article

    Metabolism and biological functions of the nitrogen-rich compound guanidine have long been neglected. The discovery of four classes of guanidine-sensing riboswitches and two pathways for guanidine degradation in bacteria hint at widespread sources of unconjugated guanidine in nature. So far, only three enzymes from a narrow range of bacteria and fungi have been shown to produce guanidine, with the ethylene-forming enzyme (EFE) as the most prominent example. Here, we show that a related class of Fe2+- and 2-oxoglutarate-dependent dioxygenases (2-ODD-C23) highly conserved among plants and algae catalyze the hydroxylation of homoarginine at the C6-position. Spontaneous decay of 6-hydroxyhomoarginine yields guanidine and 2-aminoadipate-6-semialdehyde. The latter can be reduced to pipecolate by pyrroline-5-carboxylate reductase but more likely is oxidized to aminoadipate by aldehyde dehydrogenase ALDH7B in vivo. Arabidopsis has three 2-ODD-C23 isoforms, among which Din11 is unusual because it also accepted arginine as substrate, which was not the case for the other 2-ODD-C23 isoforms from Arabidopsis or other plants. In contrast to EFE, none of the three Arabidopsis enzymes produced ethylene. Guanidine contents were typically between 10 and 20 nmol*(g fresh weight)-1 in Arabidopsis but increased to 100 or 300 nmol*(g fresh weight)-1 after homoarginine feeding or treatment with Din11-inducing methyljasmonate, respectively. In 2-ODD-C23 triple mutants, the guanidine content was strongly reduced, whereas it increased in overexpression plants. We discuss the implications of the finding of widespread guanidine-producing enzymes in photosynthetic eukaryotes as a so far underestimated branch of the bio-geochemical nitrogen cycle and propose possible functions of natural guanidine production.